Navigation Links
Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis

Managed Care Organizations Aggressively Control Access to Biologics,

According to a New Report from Decision Resources

WALTHAM, Mass., Sept. 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that specialists are turning to biologics earlier in the course of treatment for psoriasis and psoriatic arthritis. According to the new Physician & Payer Forum report entitled Psoriasis and Psoriatic Arthritis: The Expanding Biologics Landscape, surveyed dermatologists last year tried an average of 5.8 therapies for moderate psoriasis before turning to biologics. By mid-2008 they will try only 2.1 other therapies before turning to biologics. Likewise for axial psoriatic arthritis, rheumatologists tried an average of 4.1 other therapies prior to biologics last year; by mid-2008 they will only try 1.7 nonbiologics.

Specialists say the role of biologics will expand through mid-2008. Seventy-two percent of dermatologists and 90% of rheumatologists say they will write more scripts for biologics for psoriasis and psoriatic arthritis, respectively, through mid-2008. These specialists estimate that their use of biologics will increase by 9.9 percent in psoriasis and 11.9 percent in psoriatic arthritis.

In contrast to clinicians' increasingly aggressive use of biologics, the report also finds that managed care organizations (MCOs) are restricting access to biologics.

"By mid-2008, one half of surveyed MCOs' private plans will have step therapy protocols in place and 14 out of 20 surveyed MCOs will impose prior authorization for Enbrel, the leading biologic agent, for psoriasis therapy," said Joanna Kim, analyst at Decision Resources. "Physicians estimate that biologic therapy is currently delayed in 30-45% of their patients because of step therapy protocols imposed by MCOs. And overall, specialists perceive biologics to be less accessible for the treatment of psoriasis than psoriatic arthritis.

Psoriasis and Psoriatic Arthritis: The Expanding Biologics Landscape is based on a U.S. survey of 50 dermatologists, 51 rheumatologists and 20 managed care pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical and economic, factors in the management of psoriasis and Psoriatic arthritis with biologic therapies.

About Physician & Payer Forum

Physician & Payer Forum is a primary research service from Decision Resources that offers access to high-volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.


SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sonic closer to turning profit corner
2. Turning ads into sales: Context is king
3. Turning Around a Sick Company
4. GE Healthcare technology helping to detect Alzheimers earlier
5. Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins
6. Improve Recovery and Reproducibility with Pre-Treatment of Analytical TSK-GEL G3000SWXL Size Exclusion Columns
7. Quintessence cancer treatment chosen for clinical studies
8. ZyStor to exhibit cell disorder treatments
9. Radiology advance points way to non-invasive brain-cancer treatment
10. Animal testing: Beyond the protests, instances of mistreatment are rare
11. TomoTherapy leads the industry in CT image-guided treatments
Post Your Comments:
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
Breaking Biology News(10 mins):